{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:12:57Z","timestamp":1755216777775,"version":"3.43.0"},"reference-count":110,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>The prognosis of children with acute myeloid leukemia (AML) has improved incrementally over the last decades. However, at relapse, overall survival (OS) \u223c40% to 50% and is even lower for patients with chemorefractory disease. Effective and less-toxic therapies are urgently needed for these children. In the last years, immune-directed therapies such as chimeric antigen receptor (CAR)-T cells were introduced, which showed outstanding clinical activity against B-cell malignancies. CART therapies are being developed for AML on the basis of the results obtained for other hematologic malignancies. The biggest challenge of CART therapy for AML is to identify a specific target antigen, since antigens expressed in AML cells are usually shared with healthy hematopoietic stem cells. An overview of prospects of CART in pediatric AML, focused on the common antigens targeted by CART in AML that have been tested or are currently under investigation, is provided in this manuscript.<\/jats:p>","DOI":"10.1097\/mph.0000000000002956","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T07:05:36Z","timestamp":1730185536000},"page":"393-403","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Emerging CART Therapies for Pediatric Acute Myeloid Leukemia"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5998-7159","authenticated-orcid":false,"given":"Valeria","family":"Ceolin","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Regina Margherita Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Spadea","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Regina Margherita Children\u2019s Hospital"},{"name":"Department of Pediatric Oncology\/Hematology, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Apolito","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Regina Margherita Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Regina Margherita Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Fagioli","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Regina Margherita Children\u2019s Hospital"},{"name":"Department of Pediatric Oncology\/Hematology, University of Turin, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"e27605","DOI":"10.1002\/pbc.27605","article-title":"Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01","volume":"66","author":"De Moerloose","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41375-018-0314-7","article-title":"Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality","volume":"33","author":"Reedijk","year":"2019","journal-title":"Leukemia"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1200\/JCO.23.01841","article-title":"Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease","volume":"42","author":"Tierens","year":"2024","journal-title":"J Clin Oncol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J Clin Oncol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"e27542","DOI":"10.1002\/pbc.27542","article-title":"Outcome for pediatric acute promyelocytic leukemia patients at Children\u2019s Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)","volume":"66","author":"Kutny","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"e009122","DOI":"10.1161\/JAHA.118.009122","article-title":"Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study","volume":"8","author":"Feijen","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.seminoncol.2020.02.007","article-title":"Current and coming challenges in the management of the survivorship population","volume":"47","author":"Chow","year":"2020","journal-title":"Semin Oncol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"R16-20250804","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2019-130969","article-title":"Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012","volume":"134","author":"Rasche","year":"2019","journal-title":"Blood"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737140.2021.1841640","article-title":"Pediatric relapsed acute myeloid leukemia: a systematic review","volume":"21","author":"Hoffman","year":"2021","journal-title":"Expert Review of Anticancer Therapy"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41375-022-01619-9","article-title":"Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies","volume":"36","author":"Zarnegar-Lumley","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"R21-20250804","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-141774","article-title":"Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome","volume":"136","author":"Rasche","year":"2020","journal-title":"Blood"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.2018.191841","article-title":"Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group","volume":"104","author":"Niktoreh","year":"2019","journal-title":"Haematologica"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.14720","article-title":"Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia","volume":"178","author":"Karlsson","year":"2017","journal-title":"Br J Haematol"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12185-014-1616-9","article-title":"Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol","volume":"100","author":"Nakayama","year":"2014","journal-title":"Int J Hematol"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group","volume":"38","author":"Cooper","year":"2020","journal-title":"J Clin Oncol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2017.187153","article-title":"Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed\/refractory acute myeloid leukemia: a phase IB study","volume":"103","author":"van Eijkelenburg","year":"2018","journal-title":"Haematologica"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.28674","article-title":"AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia","volume":"120","author":"Cooper","year":"2014","journal-title":"Cancer"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/pbc.25117","article-title":"A Phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"e28736","DOI":"10.1002\/pbc.28736","article-title":"The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia\/Lymphoma Study Group AML-05R study","volume":"68","author":"Moritake","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/cancers13040789","article-title":"Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group","volume":"13","author":"Rasche","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.18039","article-title":"Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium","volume":"197","author":"White","year":"2022","journal-title":"Br J Haematol"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737140.2021.1841640","article-title":"Pediatric relapsed acute myeloid leukemia: a systematic review","volume":"21","author":"Hoffman","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"e27812","DOI":"10.1002\/pbc.27812","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children\u2019s Haematology Oncology Group","volume":"66","author":"Selim","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R37-20250804","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"R38-20250804","doi-asserted-by":"crossref","first-page":"eaaz046","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"R39-20250804","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","article-title":"Pediatric AML: From Biology to Clinical Management","volume":"4","author":"de Rooij","year":"2015","journal-title":"J Clin Med"},{"key":"R40-20250804","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"R41-20250804","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/biomedicines6010022","article-title":"Targeting Leukemia Stem Cells in the Bone Marrow Niche","volume":"6","author":"Tasian","year":"2018","journal-title":"Biomedicines"},{"key":"R42-20250804","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R43-20250804","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1097\/HS9.0000000000000937","article-title":"CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them","volume":"7","author":"Vanhooren","year":"2023","journal-title":"Hemasphere"},{"key":"R44-20250804","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res"},{"key":"R45-20250804","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"R46-20250804","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"R47-20250804","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"R48-20250804","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"R49-20250804","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JCO.21.01595","article-title":"CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children\u2019s Oncology Group","volume":"40","author":"Lamble","year":"2022","journal-title":"J Clin Oncol"},{"key":"R50-20250804","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood Rev"},{"key":"R51-20250804","doi-asserted-by":"crossref","first-page":"101104","DOI":"10.1016\/j.beha.2019.101104","article-title":"How close are we to CAR T-cell therapy for AML?","volume":"32","author":"Gill","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"R52-20250804","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2004-06-2416","article-title":"Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells","volume":"105","author":"Garnache-Ottou","year":"2005","journal-title":"Blood"},{"key":"R53-20250804","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1189\/jlb.0205096","article-title":"A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing","volume":"79","author":"Hern\u00e1ndez-Caselles","year":"2006","journal-title":"J Leukoc Biol"},{"key":"R54-20250804","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children\u2019s Oncology Group Trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"key":"R55-20250804","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"R56-20250804","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jcmm.13519","article-title":"Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology","volume":"22","author":"Bill","year":"2018","journal-title":"J Cell Mol Med"},{"key":"R57-20250804","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R58-20250804","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/ijms18112259","article-title":"Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia","volume":"18","author":"Laborda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R59-20250804","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R60-20250804","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fimmu.2019.00661","article-title":"NKG2D\/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment","volume":"10","author":"Frazao","year":"2019","journal-title":"Front Immunol"},{"key":"R61-20250804","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"key":"R62-20250804","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol Ther"},{"key":"R63-20250804","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther"},{"key":"R64-20250804","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R65-20250804","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor\u2013expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"R66-20250804","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4","article-title":"Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia","volume":"85","author":"Ross","year":"1999","journal-title":"Cancer"},{"key":"R67-20250804","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.V100.2.594","article-title":"Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid","volume":"100","author":"Pan","year":"2002","journal-title":"Blood"},{"key":"R68-20250804","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2022","journal-title":"Haematologica"},{"key":"R69-20250804","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2003.09.008","article-title":"C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome","volume":"28","author":"Tsao","year":"2004","journal-title":"Leuk Res"},{"key":"R70-20250804","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"key":"R71-20250804","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"key":"R72-20250804","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J Immunol"},{"key":"R73-20250804","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J Immunol"},{"key":"R74-20250804","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cam4.522","article-title":"B7-H3 protein expression in acute myeloid leukemia","volume":"4","author":"Guery","year":"2015","journal-title":"Cancer Med"},{"key":"R75-20250804","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7-H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R76-20250804","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res"},{"key":"R77-20250804","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin Transl Med"},{"key":"R78-20250804","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"R79-20250804","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","article-title":"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology","volume":"229","author":"Nolte","year":"2009","journal-title":"Immunol Rev"},{"key":"R80-20250804","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol Ther"},{"key":"R81-20250804","doi-asserted-by":"crossref","first-page":"1093750","DOI":"10.3389\/fimmu.2023.1093750","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"R82-20250804","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"R83-20250804","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"R84-20250804","first-page":"1359","article-title":"Treating Relapsed \/ Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"R85-20250804","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"R86-20250804","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-139417","article-title":"A Phase 1\/1b Safety Study of Prgn-3006 Ultracar-T\u2122 in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"R87-20250804","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"R88-20250804","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"R89-20250804","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"R90-20250804","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2023-180387","article-title":"A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed\/Refractory Acute Myeloid Leukemia in Adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"R91-20250804","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R92-20250804","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R93-20250804","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"R94-20250804","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1089\/hum.2020.216","article-title":"Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer","volume":"32","author":"Stornaiuolo","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"Supplement 1","key":"R95-20250804","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-140648","article-title":"Phase I Clinical Trial of Autologous CLL1 CAR-T Therapy for Pediatric Patients with Relapsed and Refractory Acute Myeloid Leukemia","volume":"136","author":"Bu","year":"2020","journal-title":"Blood"},{"key":"R96-20250804","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","article-title":"Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed\/Refractory Acute Myeloid Leukemia","volume":"27","author":"Zhang","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"R97-20250804","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"R98-20250804","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"R99-20250804","doi-asserted-by":"crossref","first-page":"e000845","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R100-20250804","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"issue":"Supplement 1","key":"R101-20250804","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"R102-20250804","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"R103-20250804","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"R104-20250804","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering Natural Killer Cells for Cancer Immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"R105-20250804","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"key":"R106-20250804","doi-asserted-by":"crossref","first-page":"eabm1375","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"key":"R107-20250804","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"R108-20250804","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discovery"},{"key":"R109-20250804","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"R110-20250804","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunology Research"},{"issue":"Supplement 1","key":"R111-20250804","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1182\/blood-2022-166000","article-title":"An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R\/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)","volume":"140","author":"Stein","year":"2022","journal-title":"Blood"},{"key":"R112-20250804","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:00:47Z","timestamp":1754337647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":110,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002956","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"type":"print","value":"1077-4114"},{"type":"electronic","value":"1536-3678"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"2024-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}